Results 11 to 20 of about 281,052 (341)

Paclitaxel-induced neuropathy

Annals of Oncology, 1995
Paclitaxel (Taxol) is a new antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with important activity against several tumors such as ovarian cancer, breast cancer, lung cancer and head and neck cancer. Because it promotes microtubule assembly, neuropathy occurs as one of its toxic side effects. Our purpose was to evaluate
T.J. Postma, Jan B. Vermorken, A.J.M. Liefting, Herbert M. Pinedo, J.J. Heimans   +4 more
openalex   +4 more sources

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro­pathy: a cross-sectional cohort study [PDF]

Acta Oncologica
Background and purpose: There remains limited evidence regarding the relative neurotoxic potential of nab-paclitaxel long-term. This cross-sectional matched cohort study aimed to compare the severity and natural history of chemotherapy-induced peripheral
Terry Trinh, Kimberley Au, Arun V. Krishnan, Hannah C. Timmins, Tiffany Li, Peter Grimison, David Goldstein, Susanna B. Park   +7 more
doaj   +2 more sources

Mining natural products related to paclitaxel reveals the possible biosynthetic pathway of paclitaxel [PDF]

BIO Web of Conferences, 2023
Paclitaxel is a widely used anti-tumor drug. Currently, paclitaxel can only be extracted from plants or synthesized by chemical semi-synthesis, which cause environmental damage and cannot meet the growing demand.
Sun Juncong, Deng Juntao, Song Xinfang, Gu Miao, Yang Weiyang, Liu Min   +5 more
doaj   +1 more source

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +1 more source

Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells

BMC Cancer, 2021
Background Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers.
Celina Amaya, Shihua Luo, Julio Baigorri, Rogelio Baucells, Elizabeth R. Smith, Xiang-Xi Xu   +5 more
doaj   +1 more source

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in Oncology, 2022
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cancer ...
Shen Zhao, Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin, Rongbo Lin   +16 more
doaj   +1 more source

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Biomedicines, 2023
Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities ...
Md Sazzad Hassan, Niranjan Awasthi, Saisantosh Ponna, Urs von Holzen   +3 more
doaj   +1 more source

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal, B Stordal, BK Stordal, H Kawai, H Kuroda, M Markman, S Henness, V Dieras   +7 more
core   +2 more sources

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]

, 2007
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross, Pavlakis, Nick, Stordal, Britta   +2 more
core   +1 more source

Prodrug Strategies for Paclitaxel [PDF]

International Journal of Molecular Sciences, 2016
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have ...
Xiaoqing Lv, Ziyuan Meng, Jun Lu, Quanxia Lv, Feng Jiang, Feng Jiang, Ge Zhang, Aiping Lu, Houzong Yao   +8 more
openaire   +2 more sources